

Pediatric Oncology

Dominik T. Schneider · Ines B. Brecht  
Thomas A. Olson · Andrea Ferrari *Editors*

# Rare Tumors In Children and Adolescents

 Springer

---

# Pediatric Oncology



---

Dominik T. Schneider • Ines B. Brecht  
Thomas A. Olson • Andrea Ferrari  
Editors

# Rare Tumors In Children and Adolescents

 Springer

*Editors*

Prof. Dr. Dominik T. Schneider  
Klinik für Kinder- und Jugendmedizin  
Clinic of Pediatrics  
Beurhausstr. 40  
Klinikum Dortmund  
44137 Dortmund  
Germany  
dominik.schneider@klinikumdo.de

Dr. Ines B. Brecht  
Department of Pediatric Hematology/  
Oncology  
University Children's Hospital Erlangen  
Loschgestrasse 15  
91054 Erlangen  
Germany  
ines.brecht@uk-erlangen.de

Dr. Thomas A. Olson  
Division Pediatric Hematology/Oncology  
Children's Healthcare of Atlanta at Egleston  
2015 Uppergate Drive NE, Atlanta  
GA 30322  
USA  
thomas.olson@choa.edu

Dr. Andrea Ferrari  
Pediatric Oncology Unit  
Fondazione IRCCS Istituto  
Nazionale Tumori  
Via G. Venezian 1  
20133 Milano  
Italy  
andrea.ferrari@istitutotumori.mi.it

ISBN 978-3-642-04196-9 e-ISBN 978-3-642-04197-6  
DOI 10.1007/978-3-642-04197-6  
Springer Heidelberg Dordrecht London New York

Library of Congress Control Number: 2011943617

© Springer-Verlag Berlin Heidelberg 2012

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law.

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

---

## Preface

*If you work on frequent cancers, do randomized trials!  
If you work on rare cancers – FIND FRIENDS!*

Pediatric cancers are rare events when viewed in the backdrop of all cancers. And within the scope of childhood cancers, there are more infrequent tumors that pediatric oncologists would classify as “rare pediatric tumors.” Therefore, what is the point in working on a book that specifically focuses on cancers that are “almost never” diagnosed? The most important reason may be the child who suffers with a specific tumor and the families of these children not knowing how to cope with these diagnoses.

In fact, rare cancers as a group are not as uncommon as their designation may suggest. They contribute to at least 5% of all childhood cancers. However, caring for children with such rare cancers requires a tremendous effort, primarily because sufficient information on diagnosis and therapy is missing. This book attempts to fill this information gap, by providing pediatricians, pediatric oncologists, and pediatric surgeons all currently available information required for diagnostic assessment and therapy of such patients. This book includes checklists for diagnostic procedures and detailed information on multimodal therapy of rare cancers. Thus, we hope that this book will find the interest of the international audience and will be taken to hand often, rather than rarely.

Advances in pediatric oncology have always been facilitated through sharing information and networking between experts. Networks first began among groups of institutions. Later, networks were developed on a national basis, fostered by national cooperative groups. Recently, more and more international pediatric collaborations have been established to advance prospective therapeutic trials for “more common pediatric cancers.” However, since rare tumors present with extremely low incidence, international collaboration is even more essential for these patients. Otherwise, each patient with a rare tumor will remain a “first patient” that cannot benefit from experience gathered from other patients with the same diagnosis.

Therefore, we are proud that in many aspects this book reflects the growing international collaboration in the field of rare tumors. For most chapters, authors from different national study groups have shared their knowledge and developed common recommendations. For some entities, these chapters represent the first comprehensive review in this particular entity to date. Sometimes, this has been a slow and stepwise but finally successful process. The discussions have also provided a fruitful and fantastic learning experience. We hope it may provide a framework for future evolution into internationally accepted guidelines. Finally, this book is also the result of better understanding, deeper collaboration, and growing friendship.

We would like to thank all authors for their tremendous effort in writing their chapters. We would also like to thank Springer for the opportunity to develop this project. Last, we thank our families for their continuous and loving support and their patience.

Dortmund, Germany  
Erlangen, Germany  
Atlanta, GA, USA  
Milano, Italy

Dominik T. Schneider  
Ines B. Brecht  
Thomas A. Olson  
Andrea Ferrati

---

# Contents

## Part I Introduction: Rare Cancers – A Different Perspective on Oncology

- 1 **Rare Tumors: A Different Perspective on Oncology** ..... 3  
Thomas A. Olson, Dominik T. Schneider,  
Ines B. Brecht, and Andrea Ferrari
- 2 **Showing Efficacy in Treating Rare Pediatric Tumors:  
Introduction to European Regulatory and Scientific  
Support Available to Investigators** ..... 15  
Ralf Herold and Jordi Llinares
- 3 **Rare Tumors: Pathology and Biology Perspectives.** ..... 33  
Bahig Shehata and Sarah Shulman

## Part II Epidemiology and Etiology of Rare Cancers

- 4 **Epidemiology** ..... 43  
Ines B. Brecht and Peter Kaatsch
- 5 **Biology and Etiology of Rare Pediatric Tumors.** ..... 63  
Ines B. Brecht and Johannes H.M. Merks
- 6 **Genetic Predisposition and Genetic Susceptibility** ..... 69  
Johannes H.M. Merks and Ines B. Brecht

## Part III National and International Study Groups

- 7 **France.** ..... 97  
Daniel Orbach and Yves Reguerre
- 8 **Germany** ..... 99  
Ines B. Brecht and Dominik T. Schneider
- 9 **Italy.** ..... 103  
Andrea Ferrari
- 10 **Poland.** ..... 107  
Jan Godzinski
- 11 **The United Kingdom** ..... 109  
Bernadette Brennan
- 12 **The United States** ..... 113  
Farzana D. Pashankar and Carlos Rodriguez-Galindo



<b>13</b>	<b>The EXPeRT Initiative</b> .....	117
	Gianni Bisogno	
<b>Part IV Information and Resources for Clinicians and Patients with Rare Tumors</b>		
<b>14</b>	<b>Internet Resources</b> .....	121
	Ines B. Brecht and Sonja Offenmüller	
<b>Part V Rare Tumors of the Head and Neck</b>		
<b>15</b>	<b>Differential Diagnosis of Head and Neck Tumors</b> .....	129
	Jan Godzinski and Ines B. Brecht	
<b>16</b>	<b>Thyroid Carcinomas</b> .....	133
	Maura Massimino, Antje Redlich, Paola Collini, and Peter Vorwerk	
<b>17</b>	<b>Nasopharyngeal Carcinoma</b> .....	145
	Rolf Mertens, Carlos Rodriguez-Galindo, and Michela Casanova	
<b>18</b>	<b>Esthesioneuroblastoma</b> .....	161
	Barbara Hero and Gianni Bisogno	
<b>19</b>	<b>Germ Cell Tumors of the Head and Neck</b> .....	169
	Dominik T. Schneider and Thomas A. Olson	
<b>20</b>	<b>Odontogenic Tumors</b> .....	175
	Jan Godzinski, Roberto Bianchi, and Marco Guzzo	
<b>21</b>	<b>Salivary Gland Tumors</b> .....	181
	Marco Guzzo and Jan Godzinski	
<b>22</b>	<b>Laryngeal Tumors</b> .....	187
	Roberto Bianchi, Jan Godzinski, and Marco Guzzo	
<b>Part VI Rare Tumors of the Thorax</b>		
<b>23</b>	<b>Pathological Aspects of Mediastinal Tumors</b> .....	195
	Alexander Marx and Ivo Leuschner	
<b>24</b>	<b>Mediastinal Germ Cell Tumors</b> .....	205
	Dominik T. Schneider, Giovanni Cecchetto, and Thomas A. Olson	
<b>25</b>	<b>Pleuropulmonary Blastoma</b> .....	213
	John R. Priest	
<b>26</b>	<b>Bronchial Carcinoids and Carcinomas</b> .....	223
	Michael Semik, Antje Redlich, and Peter Vorwerk	
<b>27</b>	<b>Pediatric Pleural Mesothelioma</b> .....	231
	Nicolas André, Sergey K.V.V. Kashanskiy, and Abbas Agaimy	
<b>28</b>	<b>Thymoma and Thymic Carcinoma</b> .....	239
	Jan Godzinski	

**Part VII Rare Tumors of the Gastrointestinal Tract**

- 29 Pathology and Differential Diagnosis** . . . . . 245  
Bahig M. Shehata and Sarah C. Shulman
- 30 Gastrointestinal Cancer Predisposition Syndromes** . . . . . 255  
Lucio Bertario and Stefano Signoroni
- 31 Tumors of the Esophagus and the Stomach** . . . . . 263  
Dietrich von Schweinitz
- 32 Intestinal Carcinomas** . . . . . 269  
Andrea Ferrari
- 33 Neuroendocrine Tumors of the Appendix** . . . . . 277  
Antje Redlich, Nicole Boxberger, and Peter Vorwerk
- 34 Gastrointestinal Stromal Tumors** . . . . . 279  
M. Benesch
- 35 Pancreatic Tumors** . . . . . 283  
Winfried Barthlen, Ines B. Brecht, and Bence Sipos
- 36 Liver Tumors** . . . . . 303  
Howard M. Katzenstein and Michela Casanova
- 37 Paediatric Peritoneal Mesothelioma** . . . . . 313  
Nicolas André and Abbas Agaimy
- 38 Retroperitoneal Tumors** . . . . . 321  
Ines B. Brecht and Winfried Barthlen

**Part VIII Germ Cell Tumors and Genitourinary Tumors**

- 39 Gonadal and Extragonadal Germ Cell Tumors,  
Sex Cord Stromal and Rare Gonadal Tumors** . . . . . 327  
Dominik T. Schneider, Monica Terenziani, Giovanni Cecchetto,  
and Thomas A. Olson
- 40 Rare Tumors of the Urinary Tract** . . . . . 403  
Filippo Spreafico and Norbert Graf
- 41 Breast Cancer** . . . . . 421  
Dominik T. Schneider

**Part IX Rare Tumors of the Peripheral Nervous System**

- 42 Rare Tumors of the Peripheral Nervous System** . . . . . 431  
Bernadette Brennan, Carlos Rodriguez-Galindo, and Gianni Bisogno

**Part X Rare Tumors of the Skin and Subcutaneous Tissue**

- 43 Rare Tumors of the Skin and Subcutaneous Tissues** . . . . . 455  
Alberto S. Pappo, Thomas K. Eigentler, Claus Garbe, Paola Collini,  
Andrea Ferrari, and Jochen Rössler

---

**Part XI Rare Mesenchymal Tumors**

- 44 Rare Mesenchymal Tumors** . . . . . 485  
Andrea Ferrari, Rita Alaggio, and Stefano Ferrari

**Part XII Tumors of Unknown Primary Site**

- 45 Tumors of Unknown Primary** . . . . . 521  
Thomas A. Olson

**Part XIII Rare Tumors as Second Malignancies**

- 46 Rare Subsequent Primary Cancers  
in Pediatric Cancer Survivors** . . . . . 529  
Ann C. Mertens and Thorsten Langer

- Index** . . . . . 537

---

## Part I

# Introduction: Rare Cancers – A Different Perspective on Oncology

# Rare Tumors: A Different Perspective on Oncology

1

Thomas A. Olson, Dominik T. Schneider,  
Ines B. Brecht, and Andrea Ferrari

## Contents

1.1	What Defines a Rare Tumor? .....	3
1.2	The Issue of Adult Cancers in Children .....	7
1.3	Clinical Issues in the Diagnosis and Treatment of Rare Pediatric Tumors .....	7
1.4	Delays in Diagnosis .....	8
1.5	The Challenge of Referral and Treatment .....	8
1.6	Biology .....	10
1.7	Possible Strategies in Pediatric Oncology Rare Tumors .....	11
1.7.1	Possible Solutions: "Find Friends!" .....	11
1.8	Perspective .....	12
	References .....	12

## 1.1 What Defines a Rare Tumor?

Compared to cancer in adults, childhood cancer is rare, accounting for significantly less than 1% of all cancer diagnoses. Since increasing age constitutes a significant risk factor for the development of cancer, it is supposed that the overall prevalence of cancer will continuously increase while the average life expectancy rises. In contrast, birthrates are declining in most western countries, thus leading to a further decline of the overall incidence rate of childhood cancer. Thus, the question arises, what will define a rare tumor in childhood and adolescence, if the overall numbers are generally low. Is a rare cancer defined only by incidence numbers, or do specific clinical, pathological, or biological characteristics define a tumor to be rare?

A meaningful clinical definition of a rare childhood cancer has to be developed in the context of the development of childhood cancer therapy over time. The successful treatment of children has been a remarkable accomplishment of the last 40 years. Today, approximately 75% of children diagnosed in the USA or in other countries with highly developed health care systems can be expected to be "cured" (Smith et al. 2010). This has been accomplished through extensive scientific exploration and the development of national and recently, increasingly more international clinical trials through National Cancer Institutes and national and international cooperative study groups. Fortunately, these successes have at least in parts been translated into treatment strategies, suitable and assessable for children in countries with limited economic resources.

Most early pediatric clinical trials had been conducted as national studies. This strategy worked well for leukemia, the most frequent malignant neoplasia in

---

T.A. Olson  
Division Pediatric Hematology/Oncology,  
Children's Healthcare of Atlanta at Egleston,  
2015 Uppergate Drive, N.E., Atlanta, GA 30322, USA

D.T. Schneider (✉)  
Klinik für Kinder- und Jugendmedizin, Clinic of Pediatrics,  
Beurhausstr. 40, Klinikum Dortmund, 44137 Dortmund,  
Germany  
e-mail: dominik.schneider@klinikumdo.de

I.B. Brecht  
Department of Pediatric Hematology/Oncology,  
University Children's Hospital Erlangen, Loschgestrasse 15,  
91054 Erlangen, Germany  
e-mail: ines.brecht@uk-erlangen.de

A. Ferrari  
Pediatric Oncology Unit, Istituto Nazionale Tumori,  
Via G. Venezian 1, 20133 Milano, Italy

childhood. Other cancers, with lower incidence, would require studies that might be conducted by several national groups. Slowly, collaborations evolved which incorporated several national groups into consortia. These alliances were necessary to allow randomized trials that could be completed in a reasonable period of time. Studies for Ewing's sarcoma and osteosarcoma are two such examples in which international collaborations has allowed development of randomized clinical trials, that would have been impossible on a national basis.


However, there is a hierarchy in the studies of childhood cancers. Most pediatric clinical trials involve childhood cancers that are relatively more common than other childhood cancers. More frequent cancers are "charted," whereas the rare, infrequent cancers are often not registered or reported. Some cancers, though "rare," have been studied well, but much more can still be done. Hepatoblastoma and germ cell tumors are examples of rare tumors that have established studies (Mann et al. 2000; Ortega et al. 2000; Gobel et al. 2002; Cushing et al. 2004; Perilongo et al. 2004, 2009). Still others continue outside current pediatric clinical trial structures. In a clinical and scientific perspective, these rare cancers might be classified as orphan diseases, indicating that no clinical structures have been developed to aid in diagnosis and treatment. There are also many cancers that are common in adults, yet infrequently seen in children. For some of these cancers, no specific clinical studies have been designed, but patients have been treated according to the corresponding guidelines for adult patients. From a clinical perspective, one could characterize them again, as orphan diseases.

Figure 1.1 illustrates the different epidemiological patterns of rare childhood cancers. There are some tumor types (Fig. 1.1a) that are defined by their generally extremely low incidence; nevertheless, they constitute characteristic tumors of childhood that are not diagnosed in adult patients. Well-defined examples include pancreaticoblastoma (see Chap. 35) or mesoblastic nephroma. In contrast, other types (Fig. 1.1b) may be diagnosed both during childhood and adolescents. Clinically and pathologically, they may be undistinguishable; however, molecular genetic studies may reveal biological differences, as it has been demonstrated, e.g., for germ cell tumors during in children and adults (for details see Chap. 39) (Schneider et al. 2004).

As mentioned above, some characteristic adult cancers, such as colon cancer or malignant melanoma, may also be diagnosed during childhood and adolescence (Fig. 1.1c). In general, this epidemiological pattern is characterized by a continuous increase of incidence over age. Thus, these rare childhood cancers constitute the left edge of the Gauss distribution curve of a frequent adult cancer. However, it should be noted that such cancers may also show biological and clinical characteristics that may distinguish such patients from others. Breast cancer and malignant melanomas are good examples. Both are frequent cancers in adults but infrequent in children and adolescents, and their presentation in young patients may be different from that in older patients (see Chaps. 41 and 10.2). Moreover, among young patients, there is a relatively higher proportion of patients with hereditary cancer syndromes (see Chap. 6). Therefore, it is not speculative to postulate that in some cancer types there may be a specific sub-entity of a rare childhood cancer hidden in the left edge of the Gauss distribution curve of a specific adult cancer (Fig. 1.1d).

These theoretical considerations illustrate that epidemiological investigations constitute the basis of our understanding of rare cancers. Most of our information on these "rare" tumors comes from national data sources such as Surveillance Epidemiology and End Results (SEER) database of the US National Cancer Institute (Ries et al. 1999), the German Childhood Cancer Registry (Schneider et al. 2004), or other national and international registries. In the following chapters, we will attempt to define "what constitutes a rare pediatric tumor in a both epidemiological and clinical sense" and discuss the diagnoses and possible treatments. This book will focus on both rare pediatric cancers that are indeed pediatric cancers and cancers that commonly occur in adults, but only sporadically in children. The difficulties in diagnosis and treatment of rare cancers will be emphasized.

The first question to be addressed is what constitutes a "rare" disease in an epidemiological understanding? The National Institute of Health in the USA defines a rare or orphan disease, as one with a prevalence of fewer than 200,000 individuals in the United States (<http://rarediseases.info.nih.gov>). They do clarify that subpopulations within a disease could also be considered rare. Under this definition, when compared to childhood cancer, common epithelial cancers that are diagnosed in adults would be considered a "rare" disease. One example is prostate cancer, which, despite



**Fig. 1.1** Epidemiological patterns of rare childhood cancers: (a) low incidence tumor entity occurring exclusively in children. (b) a tumor entity with bimodal age distribution and age-dependent biology. (c) an adult-type tumor entity with rare

occurrence during childhood and adolescence. d: an adult-type tumor entity with rare occurrence during childhood and adolescence but with distinct biology

more than 200,000 new diagnoses per year in the US, has been designated a “rare” disease towards which more funding should be directed. Of note, only 10,400 new cancer diagnoses are expected in 2010 among children up to 15 years of age in the USA (Table 1.1).

Regardless of the difficulties in comparing age-related and absolute incidence data for cancers in children and adults, it is obvious that the absolute number of childhood cancers, as detailed above, is dwarfed by the incidence of most adult cancers. Nevertheless, the individual impact on life expectancy is highest in children in which a cancer diagnosis shortens life expectancy by approximately 70 years compared to 9 years in prostate cancer. Thus, cancer remains the number

one health-related cause of death in children beyond the neonatal period.

The National Cancer Institute in the United States and other national cancer funding in other countries have long recognized the importance of successful treatment of childhood cancer and supported clinical trials in pediatric cancers. Pediatric groups have received sufficient support to make outstanding improvements in the survival of childhood cancer patients.

National pediatric groups have always understood that it was also their responsibility to care for children with “rare” tumors and to study the behavior of these childhood cancers. However, they have been slow to design studies for such infrequent tumors, and most of